호흡기세포융합바이러스 치료제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of respiratory syncytial virus (RSV) therapeutics Market

The global respiratory syncytial virus (RSV) therapeutics market was valued at USD 7.52 billion in 2025 and is projected to grow from USD 8.57 billion in 2026 to USD 24.28 billion by 2034, registering a CAGR of 13.90% during 2026-2034. North America dominated the market with a 35.63% share in 2025. Increasing RSV infections among infants, children, older adults, and high-risk populations, combined with growing demand for preventive and treatment therapies, is supporting market expansion.

RSV is a major cause of lower respiratory tract infections, particularly among young children. The substantial disease burden and unmet need for effective prevention and treatment have encouraged pharmaceutical companies to develop monoclonal antibodies, vaccines, and novel therapeutics. The introduction of long-acting preventive therapies and increasing research and development activities are expected to create additional opportunities throughout the forecast period.

Market Definition and Scope

The RSV therapeutics market includes medicines, preventive therapies, monoclonal antibodies, vaccines, and other pharmaceutical approaches designed to prevent or treat respiratory syncytial virus infections. The market covers therapies distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It includes both prophylactic and treatment applications across major geographic regions.

Market Dynamics

Drivers

Strategic Acquisitions and Collaborations: Pharmaceutical companies are increasingly pursuing partnerships, licensing arrangements, and acquisitions to accelerate RSV drug development and improve access to cost-effective therapies. Such collaborations can strengthen product pipelines and support commercialization.

Strong Product Pipeline: Development of long-acting monoclonal antibodies and vaccines is addressing the unmet need for RSV prevention. Nirsevimab demonstrated promising clinical results and represents the broader shift toward therapies capable of providing extended protection with fewer administrations.

Trends

Focus on Reducing Treatment Costs: Developing therapies with improved efficacy and lower treatment costs remains an important market trend. Companies are investing in novel mechanisms and collaborative R&D programs to make RSV prevention more accessible.

Expansion of Preventive Therapies: Increasing attention toward maternal vaccination and long-acting antibodies is changing the RSV prevention landscape. These approaches can provide protection to vulnerable infants and expand the role of prophylaxis within RSV care.

Restraints

Clinical Trial Failures: The development of RSV therapeutics has historically faced significant clinical challenges. Several vaccine and monoclonal antibody candidates have failed to demonstrate sufficient efficacy, increasing development risks and potentially delaying new product launches.

Impact of COVID-19

The COVID-19 pandemic disrupted pharmaceutical research and clinical development activities associated with RSV therapeutics. Patient recruitment and retention became more difficult because of restrictions and changes in healthcare utilization. The pandemic also affected RSV infection patterns and seasonal circulation, creating additional challenges for evaluating the effectiveness of investigational therapies during clinical trials.

Segmentation Analysis

By Drug Class

The market is segmented into prophylaxis and treatment. Prophylaxis represented the leading segment historically, supported by increasing adoption of preventive approaches and the development of maternal vaccines and long-acting monoclonal antibodies. The treatment segment is also expected to expand as pharmaceutical companies increase R&D activities focused on therapies for active RSV infections.

By End User

Based on end user, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies have historically accounted for a significant share because many existing RSV preventive and treatment options require administration or supervision by healthcare professionals. Growing healthcare access and pharmaceutical distribution through digital channels are expected to support the other segments.

Regional Insights

North America

North America held the largest market share of 35.63% in 2025. High RSV disease awareness, developed healthcare infrastructure, access to preventive therapies, and strong pharmaceutical R&D activities are supporting regional growth. The U.S. also experiences a substantial RSV burden among young children, contributing to continued demand for diagnosis, prevention, and treatment.

Europe

Europe is witnessing steady market expansion due to advanced healthcare infrastructure, government-supported RSV surveillance programs, and established reimbursement systems. Increasing attention toward disease burden assessment and vaccination strategies is also supporting preventive healthcare initiatives.

Asia Pacific

Asia Pacific is expected to experience considerable growth during the forecast period. Improvements in healthcare infrastructure, increasing awareness of RSV infections, and rising adoption of preventive and treatment therapies are supporting the regional market. Japan and Australia have relatively advanced healthcare systems, while developing Asian economies offer additional expansion opportunities.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa are expected to provide significant opportunities as governments focus on improving healthcare accessibility and strengthening infectious disease management. Increasing awareness and expansion of healthcare services are likely to support RSV therapeutics adoption across these regions.

Competitive Landscape

The global RSV therapeutics market has historically been concentrated among major pharmaceutical companies, while the competitive environment is evolving with the development and commercialization of newer vaccines and preventive therapies. Key companies include AstraZeneca, Bausch Health Companies, AbbVie, Johnson & Johnson, Sanofi, Merck & Co., Celltrion, mAbxience, and Enanta Pharmaceuticals.

Companies are focusing on clinical development, strategic partnerships, long-acting therapies, vaccines, and cost-effective treatment options. Product pipeline expansion and successful regulatory approvals are expected to influence the competitive structure of the market during the forecast period.

Key Industry Developments

AstraZeneca reported positive safety and tolerability results for its long-acting nirsevimab program in 2021. Moderna regained rights to its RSV vaccine candidate mRNA-1172 from Merck in 2020. In 2019, Janssen Pharmaceutical Companies received Breakthrough Therapy Designation for its investigational RSV prophylactic vaccine candidate intended for older adults.

Report Coverage

The RSV therapeutics market report provides qualitative and quantitative analysis of market size, growth, segmentation, regional performance, market dynamics, competitive developments, product pipelines, and the impact of COVID-19. It covers prophylaxis and treatment applications, end-user channels, regional market trends, and major companies involved in RSV therapeutics development.

Conclusion

The global respiratory syncytial virus therapeutics market is positioned for substantial expansion, increasing from USD 7.52 billion in 2025 to USD 8.57 billion in 2026 and reaching USD 24.28 billion by 2034. The market's growth is supported by the persistent RSV disease burden, increasing demand for preventive therapies, expanding clinical pipelines, and pharmaceutical investments in long-acting antibodies and vaccines. North America remains a major market, while Asia Pacific, Europe, Latin America, and the Middle East & Africa are providing additional opportunities through improving healthcare infrastructure and greater RSV awareness. Continued innovation, successful clinical development, strategic collaborations, and broader access to preventive therapies are expected to remain important factors shaping the RSV therapeutics industry through 2034.

Unit Value (USD million)

Segmentation By Drug Class

• Prophylaxis
  • Palivizumab
  • Nirsevimab
  • MK-1654
  • Other Prophylaxis
• Treatment
  • Ribavirin
  • JNJ 53718678
  • Enanta EDP-938
  • ASCENIV

By End User

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
• 4.2. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
• 4.3. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
• 4.4. Potential Vaccine Candidates and Potential Impact of Approvals on the Treatment Market
• 4.5. Trends: Changing Landscape Treatment & Prophylaxis, Unmet Needs, etc.
• 4.6. Total Number of Patients Receiving Palivizumab, Key Countries/ Region
• 4.7. Impact of Covid-19 on the Market

5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Prophylaxis
    • 5.2.1.1. Palivizumab
    • 5.2.1.2. Nirsevimab
    • 5.2.1.3. MK-1654
    • 5.2.1.4. Other Prophylaxis (Vaccines)
  • 5.2.2. Treatment
    • 5.2.2.1. Ribavirin
    • 5.2.2.2. All New Treatment
      • 5.2.2.2.1. JNJ 53718678
      • 5.2.2.2.2. Enanta EDP-938
      • 5.2.2.2.3. ASCENIV
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Retail Pharmacies
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Country
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Drug Class
  • 6.2.1. Prophylaxis
    • 6.2.1.1. Palivizumab
    • 6.2.1.2. Nirsevimab
    • 6.2.1.3. MK-1654
    • 6.2.1.4. Other Prophylaxis (Vaccines)
  • 6.2.2. Treatment
    • 6.2.2.1. Ribavirin
    • 6.2.2.2. All New Treatment
      • 6.2.2.2.1. JNJ 53718678
      • 6.2.2.2.2. Enanta EDP-938
      • 6.2.2.2.3. ASCENIV
• 6.3. Market Analysis - By End User
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Retail Pharmacies
  • 6.3.3. Online Pharmacies
• 6.4. Market Analysis - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Drug Class
  • 7.2.1. Prophylaxis
    • 7.2.1.1. Palivizumab
    • 7.2.1.2. Nirsevimab
    • 7.2.1.3. MK-1654
    • 7.2.1.4. Other Prophylaxis (Vaccines)
  • 7.2.2. Treatment
    • 7.2.2.1. Ribavirin
    • 7.2.2.2. All New Treatment
      • 7.2.2.2.1. JNJ 53718678
      • 7.2.2.2.2. Enanta EDP-938
      • 7.2.2.2.3. ASCENIV
• 7.3. Market Analysis - By End User
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis - By Country
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Drug Class
  • 8.2.1. Prophylaxis
    • 8.2.1.1. Palivizumab
    • 8.2.1.2. Nirsevimab
    • 8.2.1.3. MK-1654
    • 8.2.1.4. Other Prophylaxis (Vaccines)
  • 8.2.2. Treatment
    • 8.2.2.1. Ribavirin
    • 8.2.2.2. All New Treatment
      • 8.2.2.2.1. JNJ 53718678
      • 8.2.2.2.2. Enanta EDP-938
      • 8.2.2.2.3. ASCENIV
• 8.3. Market Analysis - By End User
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis - By Country
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Drug Class
  • 9.2.1. Prophylaxis
    • 9.2.1.1. Palivizumab
    • 9.2.1.2. Nirsevimab
    • 9.2.1.3. MK-1654
    • 9.2.1.4. Other Prophylaxis (Vaccines)
  • 9.2.2. Treatment
    • 9.2.2.1. Ribavirin
    • 9.2.2.2. All New Treatment
      • 9.2.2.2.1. JNJ 53718678
      • 9.2.2.2.2. Enanta EDP-938
      • 9.2.2.2.3. ASCENIV
• 9.3. Market Analysis - By End User
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Analysis - By Country
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Drug Class
  • 10.2.1. Prophylaxis
    • 10.2.1.1. Palivizumab
    • 10.2.1.2. Nirsevimab
    • 10.2.1.3. MK-1654
    • 10.2.1.4. Other Prophylaxis (Vaccines)
  • 10.2.2. Treatment
    • 10.2.2.1. Ribavirin
    • 10.2.2.2. All New Treatment
      • 10.2.2.2.1. JNJ 53718678
      • 10.2.2.2.2. Enanta EDP-938
      • 10.2.2.2.3. ASCENIV
• 10.3. Market Analysis - By End User
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Analysis - By Country
  • 10.4.1. GCC Countries
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. AstraZeneca
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Bausch Health Companies Inc
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. AbbVie
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Johnson & Johnson Services, Inc.
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Sanofi
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Merck & Co., Inc
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Celltrion Inc.
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. mAbxience
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Enanta Pharmaceuticals, Inc
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)

12. Strategic Recommendations